Source - GNW

Bagsværd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on 23 March 2017, it was decided to reduce the company's B share capital from DKK 402,512,800 to DKK 392,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. 

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 500,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 392,512,800.

The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.

Further information

Media:    
Anne Margrethe Hauge +45 3079 3450 [email protected]
 

Investors:
   
Peter Hugreffe Ankersen +45 3075 9085 [email protected]
Hanna Ögren
Anders Mikkelsen
Kasper Veje (US)
+45 3079 8519
+45 3079 4461
+1 609 235 8567
[email protected]
[email protected]
[email protected]

Company announcement No 29 / 2017 





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire